SKF divests aerospace operation in Elgin to Carco PRP Group

SKF has agreed to divest its precision elastomeric device (PED) operation in Elgin, Illinois, to Carco PRP Group for approximately $70 million, an operation that generated SEK 260 million in 2024 sales. This divestment, following a prior sale, completes SKF's strategic exit from non-core aerospace businesses. The company will now concentrate on its core aeroengine and aerostructure bearing offerings, which represent SEK 6 billion in annual sales, planning increased investments in digitalization and modernization for these areas. The transaction is expected to close in Q4 2025, pending regulatory approval.

Analysis

SKF is executing a strategic refinement of its aerospace division by divesting its non-core precision elastomeric device (PED) operation for approximately $70 million. This unit, which generated SEK 260 million in 2024 sales, is being sold at an implied price-to-sales multiple of roughly 2.7x. This transaction, expected to close in Q4 2025, marks the completion of SKF's planned divestiture program within its aerospace strategic review, following the earlier sale of its Hanover operation. The move sharpens the company's focus on its significantly larger core aeroengine and aerostructure bearing segments, which account for approximately SEK 6 billion in annual sales. Management has explicitly stated its intention to redeploy capital and resources toward strengthening this core business through investments in digitalization, automation, and factory modernization, signaling a clear strategy to enhance competitiveness and operational efficiency in its primary markets.

Key Decisions for Investors

• Investors should view this divestment positively as it completes a strategic restructuring, simplifying the business and focusing management on the high-value core aerospace bearing market.
• The key performance indicator to monitor is now the operational execution within the core SEK 6 billion aerospace business, specifically looking for margin improvement or market share gains resulting from the planned investments in modernization and digitalization.
• The expected cash infusion of approximately SEK 700 million in Q4 2025 will strengthen the balance sheet to fund these strategic initiatives, and the transaction provides a useful valuation benchmark for the company's non-core assets.